Do you want to read an article? Please log in or register.
COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports
Further Publications
Related content
Further Publications
COVID-19 and the Cerebro-Cardiovascular Systems: What do we Know so Far?
J Am Heart Assoc.
Larson AS, Savastano L, Kadirvel R, Kallmes DF, Hassan AE, Brinjikji W
doi: 10.1161/JAHA.120.016793.
Further Publications
The Science Underlying COVID-19: Implications for the Cardiovascular System
Circulation.
Liu PP, Blet A, Smyth D, Li H
doi: 10.1161/CIRCULATIONAHA.
Cardiovascular Risk and Diseases
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic
J Am Coll Cardiol.
Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, Brown TS, Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA
doi: 10.1016/j.jacc.2020.03.031.
Cardiovascular Risk and Diseases
Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors
J Am Heart Assoc.
Gupta AK, Jneid H, Addison D, Ardehali H, Boehme AK, Borgaonkar S, Boulestreau R, Clerkin K, Delarche N, DeVon HA, Grumbach IM, Gutierrez J, Jones DA, Kapil V, Maniero C, Mentias A, Miller PS, May Ng S, Parekh JD, Sanchez RH, Teodor Sawicki K, S J M Te Riele A, Ann Remme C, London B
doi: 10.1161/JAHA.120.017013.
RECOMMENDED
Cardiovascular Risk and Diseases
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Eur Heart J
Task Force for the management of COVID-19 of the European Society of Cardiology .
doi: 10.1093/eurheartj/ehab697
Hypertension
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
Hypertension.
Danser AHJ, Epstein M, Batlle D
doi: 10.1161/HYPERTENSIONAHA.
Further Publications
Renin-Angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry
Am Heart J
Núñez-Gil IJ, Olier I, Feltes G, Viana-Llamas MC, Maroun-Eid C, Romero R, Fernández-Rozas I, Uribarri A, Becerra-Muñoz VM, Alfonso-Rodriguez E, García-Aguado M, Elola J, Castro-Mejía A, Pepe M, Garcia-Prieto JF, Gonzalez A, Ugo F, Cerrato E, Bondia E, Raposeiras S, Mendez JLJ, Espejo C, Masjuan ÁL, Marin F, López-Pais J, Abumayyaleh M, Corbi-Pascual M, Liebetrau C, Ramakrisna H, Estrada V, Macaya C, HOPE COVID-19 investigators (Cols appendix).
doi: 10.1016/j.ahj.2021.04.001
Hypertension
Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis
Hypertension.
Guo X, Zhu Y, Hong Y
doi: 10.
RECOMMENDED
Cardiovascular Risk and Diseases
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Eur Heart J
Task Force for the management of COVID-19 of the European Society of Cardiology .
doi: 10.1093/eurheartj/ehab696